Sourced from licensed compounding pharmacies
Arpino, G., Bardou, V
A monster created Ozempic If youve benefitted from the medications Ozempic, Wegovy, and others like them to treat diabetes and support weight management, thank the Gila monster
The absolute risk reduction remained clinically significant even at 24 months, with the semaglutide group maintaining consistently lower risk profiles across all outcomes
Key benefits Why people compare it 1 22.5% mean body weight reduction at 15mg in SURMOUNT-1 (N=2,539, 72 weeks) 2 Dual GIP/GLP-1 receptor activation for combined metabolic effects beyond single-agonist therapy 3 63% of participants at highest dose achieved at least 20% weight loss vs 1.3% placebo 4 Superior A1C reduction of 2.07-2.59% with up to 97% of diabetic participants reaching target 5 Outperformed semaglutide 1mg head-to-head in SURPASS-2 for both weight and glycemic endpoints 6 Enhanced adipose tissue lipid handling and fat redistribution via GIPR signaling 7 Significant improvements in triglycerides, blood pressure, and waist circumference across all doses 8 Once-weekly dosing supported by 120-hour half-life and C20 fatty diacid albumin binding Deep research Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813.45 Da
Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP
